Applying Data to Patient Care: Case Review in Follicular Lymphoma

Applying Data to Patient Care: Case Review in Follicular Lymphoma

Applying Data to Patient Care: Case Review in Follicular Lymphoma
RestartResume

Explore a case of R/R follicular lymphoma to find out how available and emerging treatment strategies can be used to optimize outcomes for patients.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Recent clinical trial evidence supports the use of available and emerging options in relapsing/refractory follicular lymphoma. In this case-based activity, Dr. Loretta Nastoupil and Dr. John Leonard discuss the importance of testing for EZH2 mutations in follicular lymphoma, choosing the appropriate treatment option for each patient, and how to minimize risk to improve patient outcomes.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Loretta J. Nastoupil, MD
    Associate Professor, Department of Lymphoma/Myeloma
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Contracted Research: BMS/Celgene, Epizyme, Genentech, Janssen, Novartis
    Consulting Fees: ADC, Bayer, BMS/Celgene, Epizyme, Genentech, Gilead, Janssen, MorphoSys

    Faculty:
    John P. Leonard, MD
    The Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
    Weill Cornell Medicine
    New York, NY

    Consulting Fees: AbbVie, AstraZeneca, Bayer, BMS, Celgene, Epizyme, Genmab, Genentech/Roche, Gilead, Incyte, Janssen, Karyopharm, Miltenyi, Regeneron, Sutro

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest in Vertex Pharmaceuticals.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objective

    After participating in this educational activity, participants should be better able to:

    • Formulate strategies that optimize therapy outcomes for patients with relapsing/refractory follicular lymphoma with or without EZH2 mutations
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists and hematologist oncologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Epizyme.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free